Thus, according to the results of our research, taking ALA for 4 months in patients with type 2 diabetes who underwent non-Q-MI reduced the activity of systemic inflammation and did not significantly affect the content of anti-inflammatory IL-10 in these patients. The gene discussed is IL10; the disease is type 2 diabetes mellitus.